M. Kostapanos

发表

Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects

Nicole Lewis, W. Spreen, Y. Lou, 2019, Antiviral therapy.

Small dense LDL cholesterol and apolipoproteins C-II and C-III in non-diabetic obese subjects with metabolic syndrome

M. Elisaf, T. Filippatos, D. Kiortsis, 2008 .

Low-dose interleukin-2 in patients with stable ischaemic heart disease and acute coronary syndromes (LILACS): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase I/II clinical trial

J. H. Rudd, Emma L. Arbon, K. Burling, 2018, BMJ Open.

Regulatory T-Cell Response to Low-Dose Interleukin-2 in Ischemic Heart Disease.

J. H. Rudd, M. Clatworthy, D. Klatzmann, 2021, NEJM evidence.

Listeria monocytogenes infection two days after infliximab initiation in a patient with ulcerative colitis

M. Elisaf, C. Zois, K. Katsanos, 2010 .

Baricitinib set to join the Covid-19 therapeutic arsenal?

I. Wilkinson, A. Cope, J. Galloway, 2021, Rheumatology.

muLTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19-Experimental drugs and mechanisms (TACTIC-E): A structured summary of a study protocol for a randomized controlled trial

I. Wilkinson, A. Cope, S. Norton, 2020, Trials.

Repurposed immunomodulatory drugs for Covid-19 in pre-ICu patients - mulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19 – Repurposed Drugs (TACTIC-R): A structured summary of a study protocol for a randomised controlled trial

I. Wilkinson, A. Cope, S. Norton, 2020, Trials.

Advanced imaging for quantification of abnormalities in the salivary glands of patients with primary Sjögren’s syndrome

G. Searle, L. Kershaw, Coziana Ciurtin, 2020, Rheumatology.

Investigating the Lowest Threshold of Vascular Benefits from LDL Cholesterol Lowering with a PCSK9 mAb Inhibitor (Alirocumab) in Patients with Stable Cardiovascular Disease (INTENSITY-HIGH): protocol and study rationale for a randomised, open label, parallel group, mechanistic study

I. Wilkinson, C. McEniery, E. Vamvaka, 2021, BMJ Open.

Comparison of the Pharmacokinetics of RIPK1 Inhibitor GSK2982772 in Healthy Western and Japanese Subjects

A. S. Gross, D. Tompson, C. Davies, 2020, European journal of drug metabolism and pharmacokinetics.

Clinical research Small dense LDL cholesterol and apolipoproteins C-II and C-III in non-diabetic obese subjects with metabolic syndrome

M. Elisaf, T. Filippatos, D. Kiortsis, 2008 .

Low dose interleukin-2 in patients with stable ischaemic heart disease and acute coronary syndrome (LILACS)

J. H. Rudd, D. Klatzmann, E. Vamvaka, 2020 .

Small dense LDL cholesterol and apolipoproteins C-II and C-III in non-diabetic obese subjects with metabolic syndrome

M. Elisaf, T. Filippatos, D. Kiortsis, 2008 .

Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial

J. Graggaber, G. Boehmer, G. Koduri, 2023, The Lancet. Respiratory medicine.